Imagine learning that your newborn baby has a rare, life-altering condition that could have been detected earlier—a condition that, if left untreated, could drastically shorten their life. This is the heartbreaking reality Jesy Nelson, the former Little Mix singer, is facing after her twin daughters were diagnosed with Spinal Muscular Atrophy (SMA). But here’s where it gets controversial: despite the existence of life-saving treatments, SMA is not currently included in the standard NHS newborn screening test. Now, Nelson is on a mission to change that, and her fight is sparking a much-needed conversation about early detection and healthcare priorities.
The Heart of the Matter
In an emotional Instagram post, Nelson revealed that her seven-month-old daughters, Ocean Jade and Story Monroe Nelson-Foster, have been diagnosed with SMA, a devastating genetic disorder that affects muscle movement, including breathing and swallowing. She described the past few months as a grueling journey of endless appointments, culminating in the news that her girls will likely never walk or regain full neck strength. “It’s the most severe muscular disease,” she explained, emphasizing that without timely treatment, children with SMA often don’t survive past age two.
But here’s the part most people miss: While treatments like Zolgensma—a groundbreaking gene therapy approved by the NHS in 2021—can be life-changing, their effectiveness hinges on early intervention. If SMA is detected too late, irreversible damage to the nervous system may already have occurred. This is why Nelson is campaigning to add SMA to the NHS newborn blood spot test, which currently screens for 10 other conditions but not SMA.
A Call to Action
Nelson has launched a petition urging the NHS to include SMA in the heel prick test conducted on newborns at five days old. “I’m going to fight as much as I can to make this part of the newborn screening,” she declared, adding that the issue is currently under review. Her determination has resonated with thousands, and she’s been overwhelmed by the support from families facing similar challenges. “Thank you from the bottom of my heart,” she said, acknowledging the outpouring of love and solidarity.
The Broader Debate
Nelson’s campaign has already caught the attention of Health Secretary Wes Streeting, who acknowledged her right to challenge the system’s slow diagnosis process. He pledged to explore not only SMA screening but also the broader use of genomic medicine in healthcare. Meanwhile, Scotland is set to begin routine SMA screening for newborns this spring, raising questions about why the rest of the UK hasn’t followed suit.
Here’s where it gets even more contentious: While the NHS has introduced three new SMA treatments since 2019, benefiting hundreds of children, critics argue that early detection is the missing piece of the puzzle. An NHS spokesperson confirmed that the National Screening Committee is reviewing the possibility of routine SMA screening, but the process has been slow. The Generation Study is also investigating whether genomic sequencing could become a standard part of newborn screening, including for SMA.
A Question for You
Should SMA screening be a priority for the NHS, or are there more pressing healthcare issues that deserve attention? Nelson’s campaign highlights the delicate balance between advancing medical technology and ensuring equitable access to life-saving interventions. What do you think? Is early detection of rare diseases like SMA worth the investment, or should resources be allocated elsewhere? Let’s keep the conversation going—because every baby deserves a fighting chance.
